Literature DB >> 21526897

Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.

Daniela Masciocchi1, Arianna Gelain, Stefania Villa, Fiorella Meneghetti, Daniela Barlocco.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is an oncogenic protein whose inhibition is sought for the prevention and treatment of cancer. In this review, the validated therapeutic strategy to block aberrant activity of STAT3 in many tumor cell lines is evaluated by presenting the most promising inhibitors to date. The compounds are discussed in classes based on their different mechanisms of action, which are critically explained. In addition, their future clinical development as anticancer agents is considered. Furthermore, the efforts devoted to the comprehension of the structure-activity relationships and to the identification of the biological effects are brought to attention. The synthetic and technological approaches recently developed to overcome the difficulties in the obtainment of clinically suitable drugs are also presented.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21526897     DOI: 10.4155/fmc.11.22

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  24 in total

1.  Rap1GAP regulates renal cell carcinoma invasion.

Authors:  Wan-Ju Kim; Zachary Gersey; Yehia Daaka
Journal:  Cancer Lett       Date:  2012-01-20       Impact factor: 8.679

Review 2.  Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.

Authors:  Shanchun Guo; Mingli Liu; Guangdi Wang; Marta Torroella-Kouri; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2012-01-24

3.  Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.

Authors:  Leslie van der Fits; Jacoba J Out-Luiting; Cornelis P Tensen; Willem H Zoutman; Maarten H Vermeer
Journal:  J Invest Dermatol       Date:  2014-04-22       Impact factor: 8.551

4.  Two serine residues of non-metastasis protein 23-H1 are critical in inhibiting signal transducer and activator of transcription 3 activity in human lung cancer cells.

Authors:  Zhihao Wu; Lili Guo; Jiangnan Ge; Zhijian Zhang; Huijun Wei; Qinghua Zhou
Journal:  Oncol Lett       Date:  2017-06-09       Impact factor: 2.967

5.  Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.

Authors:  Murali K Urlam; Roberta Pireddu; Yiyu Ge; Xiaolei Zhang; Ying Sun; Harshani R Lawrence; Wayne C Guida; Saïd M Sebti; Nicholas J Lawrence
Journal:  Medchemcomm       Date:  2013-06       Impact factor: 3.597

6.  A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation.

Authors:  Xiaolei Zhang; Ying Sun; Roberta Pireddu; Hua Yang; Murali K Urlam; Harshani R Lawrence; Wayne C Guida; Nicholas J Lawrence; Saïd M Sebti
Journal:  Cancer Res       Date:  2013-01-15       Impact factor: 12.701

7.  STAT3 protein up-regulates Gα-interacting vesicle-associated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis.

Authors:  Ying Dunkel; Andrew Ong; Dimple Notani; Yash Mittal; Michael Lam; Xiaoyi Mi; Pradipta Ghosh
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

8.  Identification of novel inhibitors that disrupt STAT3-DNA interaction from a γ-AApeptide OBOC combinatorial library.

Authors:  Peng Teng; Xiaolei Zhang; Haifan Wu; Qiao Qiao; Said M Sebti; Jianfeng Cai
Journal:  Chem Commun (Camb)       Date:  2014-06-25       Impact factor: 6.222

9.  A novel small inhibitor, LLL12, targets STAT3 in non-small cell lung cancer in vitro and in vivo.

Authors:  Yanli Nie; Yuanyuan Li; Sheng Hu
Journal:  Oncol Lett       Date:  2018-08-03       Impact factor: 2.967

10.  2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway.

Authors:  Matthew G LaPorte; Dimas José da Paz Lima; Feng Zhang; Malabika Sen; Jennifer R Grandis; Daniel Camarco; Yun Hua; Paul A Johnston; John S Lazo; Lynn O Resnick; Peter Wipf; Donna M Huryn
Journal:  Bioorg Med Chem Lett       Date:  2014-09-15       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.